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Abstract 
Triple Negative Breast Cancer (TNBC) is a rare basal-like subtype of breast cancer characterized 
by the absence of the estrogen (ER), progesterone (PR), and human epidermal receptor 2 (HER2) 
receptors which are normally targeted in other breast cancer subtypes, thereby making TNBC 
difficult to combat.  In this study, four different styrene compounds (1.001, 1.006, 1.007, and 
1.009) were used to treat TNBC cell lines HCC1806 and HCC70. Each of the compounds were 
composed of a 3-nitro group on the A ring and varying aryl groups on the B ring of the styrene.  
The breast cancer cells were exposed over a 24-hour period to a 10, 100 and 1000 µM styrene 
concentration.  Styrene compounds have a similar structural composition to Resveratrol and 
some known Poly (adenosine diphosphate (ADP)-ribose) Polymerase (PARP) inhibitors. 
Previous studies have demonstrated that PARP-1 has a high affinity for breast cancer 
susceptibility gene-deficient (BRCA) breast carcinomas such as TNBC.  Similarities in structure 
suggest that these compounds may have the same apoptotic effect found in PARP inhibitors used 
in treating cancer.  A cell viability assay revealed that all of the styrene compounds were 
effective and showed apoptosis at varying concentrations in-vitro. Apoptosis was also verified 
with phase-contrast microscopy and Methylthiazol Tetrazolium (MTT) Assay.  PARP inhibition 
by styrenyl compounds was verified with the HT Fluorescent Homogenous PARP Inhibition 
Assay. Preliminary data show that these compounds have the ability to induce apoptosis in triple 
negative cells and lead us to believe these compounds represent a novel potential 
chemotherapeutic treatment for TNBC. 
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CHAPTER 1  
Introduction 
 Cancer is a disease characterized by excessive, uncontrolled growth of abnormal cells 
that invade and destroy other adjacent tissues.  Cancer can also spread to other regions of the 
body, through metastasis, on the same seek and destroy mission.  Cancer can develop in any 
tissue of any organ at any age and in any race/ethnicity.  Various factors influence the onset of 
this disease, which can include gender, geography, genetics and cultural distinctions.  Such 
factors play an important role in the effect that cancer has on the general population and its 
prevalence. 
 In the United States, cancer is the second most common cause of deaths, accounting for 
nearly 1 of every 4 deaths (American Cancer Society, 2012).   Breast cancer is the 2nd leading 
cause of cancer death of women in the United States, according to the National Cancer Institute 
(NCI) (National Cancer Institute, Breast). Triple Negative Breast Cancer (TNBC) has a mortality 
rate that increases in at least one-fourth of those diagnosed and is a rare type of breast cancer that 
is more prevalent in younger women of color (African American and Hispanic).  TNBC is 
characterized by the absence of ER, PR, and HER2 receptors. Triple negative breast cancer lacks 
effective therapies due to lack of specific biomarkers. Well-known treatments for breast cancer 
are unable to combat TNBC and often reappear in a more aggressive form. Therefore, the need 
for novel chemotherapeutic options, other than chemotherapy, in TNBC still remains. Styrene is 
a potential chemotherapeutic option for TNBC due to its similar PARP inhibitor characteristics.  
As a PARP inhibitor, styrene has the ability to attack the cells at the molecular DNA level.  
Previous literature has identified PARP inhibitors such as Olaparib that produced significant 
results in treating triple negative breast cancer (Fong, 2009). Styrenyl compounds also have a 
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similar structure to resveratrol and similarities in structure leads to the impression that styrene 
will provide the same results in TNBC. 
 The purpose of this study is to identify a potential novel therapeutic for triple negative 
breast cancer.  With styrenes as our prominent chemical compounds, the objective is to 
determine the styrene compounds with the effective working concentration that produces a 
measurable apoptotic effect in triple negative breast cancer.  The hypothesis is that these styrenyl 
compounds will produce a measurable apoptotic effect at a low minimum working concentration.  
As an increasingly widespread type of cancer that has been growing in diagnostics and mortality, 
the need for therapeutic options is still needed to diminish the odds and slow down these death 
rates of TNBC patients.  Thus the significance of this study is to reduce the gap in therapeutic 
treatment options for TNBC. 
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CHAPTER 2 
Literature Review 
2.1  Cancer 
 Cancer, defined as the disease caused by an uncontrolled division of abnormal cells in a 
part of the body, is primarily caused by environmental factors (90-95%) while the remaining 
causes are due to genetics (5-10%).  Some common environmental factors include tobacco, diet, 
obesity, infections, radiation, stress, lack of physical activity, and pollutants.  Yet, with all these 
different risk factors, cancer is not caused by only one component.  Cancer tends to develop 
because of numerous factors, also known as the ‘multi-hit theory.’ 
  In the multi-hit theory an accumulation of mutations causes the formation of cancer.  
These mutations can include random, inherited (pre-disposed), viral infections, or environmental 
factors (chemical/physical).  Although cancer may begin with just one mutation, one is not 
enough.  A correlation between age and the incidence of cancer further justify the multi-step 
process involved with cancer development.  As age increases, chromosomal abnormalities occur 
and genes are further mutated.  Oncogenes that normally promote cell proliferation are actively 
mutated, while tumor suppressor genes that normally inhibit cell proliferation are inactively 
mutated.  Due to the different ‘hits’ or mutations that can occur to a cell, the theory of cancer 
development is further justified. 
 An estimation of 1.6 million new cancer cases are expected to be diagnosed in 2013 and 
out of these, 580,350 Americans are expected to die (Siegal, 2013).  Since the risk of being 
diagnosed increases with age, most cases occur in adults who are middle age or older.  About 
77% of all cancers are diagnoses in persons 55 years of age and older.  Yet with continued 
research and early diagnoses, the 5-year survival rate for all cancer diagnoses has increased from 
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49% in 1975-1977, to 67% in 2001-2007 and is continuously rising (American Cancer Society, 
2012).  The National Cancer Institute estimates that nearly 12 million Americans were alive in 
January 2008 with a history of cancer.  According to the National Institute of Health (NIH) the 
overall estimate cost of cancer in 2007 was  $226.8 billion, including direct medical cost ($103.8 
billion) and indirect mortality cost ($123.0 billion).  With great investment being spent into 
cancer many types take precedence over others, which in turn require the bulk of the investment 
as well as the attention. 
 Each organ in the body is made up of different types of tissue.  Most cancers arise in one 
of three main types of tissues: blood forming, connective or epithelial.  Sarcomas represent less 
than 2% of cancers and originate within connective tissue.  Two types combined account for 8% 
of cancers develop in blood cells (leukemia) and the lymphatic system (lymphomas).  90% of all 
human carcinomas occur in the epithelial tissue throughout the body (Sperry, 2009). 
 Carcinoma is a term often used interchangeably with cancer.  Typically carcinomas are 
identified based on its type and organ of origination.  Some of the most frequently diagnosed 
cancers in the United States include: melanomas, bladder, prostate, colon and rectal, lung and 
breast.  Melanoma is a form of skin cancer that begins in the melanocytes and has an estimated 
76,250 new cases in 2013 (National Cancer Institute, Melanoma).  Bladder cancer forms in the 
tissues of the bladder and begins in the cells that normally make up the inner lining of the 
bladder, such as, squamous cells and adenocytes.  These cells can develop squamous cell 
carcinoma and adenocarcinoma in the inner lining of the bladder as a result of chronic irritation 
and inflammation.  The estimated new cases in the US were 73,510 in 2013 (National Cancer 
Institute, Bladder). Prostate cancer forms in the tissue of the male reproductive gland found 
below the bladder and in front of the rectum.  This cancer usually occurs in older men and was 
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estimated to have 241,740 new cases in 2013 (National Cancer Institute, Prostate).  Colon and 
rectal carcinoma forms in the respective organs.  Most colon cancers are adenocarcinomas, a 
cancer that begins in the cells that make and release mucus and other fluids.  The estimated 
amount of new cases in 2013 was 103,170 (colon) and 40,290 (rectal) (National Cancer Institute, 
Colon).  Lung cancer forms usually in the cells lining air passages.  Two of the main types are 
small cell and non-small cell lung cancer, which are diagnosed based upon its appearance under 
the microscope.   The estimated amount of new cases in 2013 was 226,160.  This type of cancer 
is the leading cause of cancer deaths, estimated to the amount of 160,340 (National Cancer 
Institute, Lung).  Breast cancer forms usually in the ducts and lobules of the breast.  This cancer 
occurs in both men and women and 226,870 (females) and 2,190 (males) new cases were 
estimated in 2013 (National Cancer Institute, Breast).  Breast cancer is the second leading cause 
of death in the United States and unlike the preventability of lung cancer as the leading cause of 
cancer deaths; breast cancer results from other non-preventable causes.   
2.2  Breast Cancer 
 Although breast cancer can develop in both men and women, women are the most 
frequently diagnosed.  Understanding the structure of the breast helps one appreciate the 
development of breast cancer in these women.  Each breast has 15-20 sections known as lobes 
that are arranged like the petals of daisy (Figure 1).  Each lobe has many smaller lobules, which 
end in dozens of tiny bulbs that can produce milk.  The ducts, or thin tubes, link all the lobes, 
lobules and bulbs.  These ducts lead to the nipple in the center of a dark area of skin called the 
areola.  Fat occupies the space found in between the lobules and ducts and no muscles are found 
in the breast, but rather under the breast to cover the ribs.  Each breast also contains blood and 
lymph vessels.  The lymph vessels lead to the lymph nodes, the organs found under the arm, 
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above the collarbone, in the chest and many other parts of the body (The Ohio State).  Once an 
individual is able to comprehend the anatomy of the breast, they can tackle diagnosing and 
treating the many forms of breast cancer found in many women. 
 
Figure 1. Anatomy of the Breast   
 Along with the amount of invasive breast cancers, 63,300 new cases of in situ breast 
cancers were estimated to occur among women in 2012 (American Cancer Society, 2012).  
However since 2004, in situ breast cancer incidence rates have been stable in white women and 
increasing in African American women by 2.0% per year (American Cancer Society, 2012).  The 
death rates have also steadily decreased in women since 1990; from 2004 to 2008, women 
younger than 50 have had rates decrease by 3.1% per year and women 50 and older, 2.1% per 
year.  The decrease in breast cancer mortality represents the progress in earlier detection, 
improved treatment therapies, and the possibility of decreased incidence.  In 2012, an estimated 
39,920 breast cancer deaths were expected (American Cancer Society, 2012).  These estimations 
include all invasive and in situ breast cancer subtypes that effect women of all races and ages. 
 There are several different types of breast cancer that originate in different areas of the 
breast.  Breast cancer is categorized into non-invasive or invasive.  In non-invasive breast cancer 
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abnormal cells grow inside the milk ducts but do not spread to nearby tissue (Susan G. Komen 
Foundation, 2013a).  Abnormal cells from inside the ducts or lobules breaking out and spreading 
into nearby breast tissue characterize invasive breast cancer.  This allows the cancerous cells to 
spread to lymph nodes and in advanced stages propagate to other organs throughout the body.  
Molecularly, breast cancer is further classified into four major subtypes: luminal A, luminal B, 
HER2 type and basal-like. 
 Luminal A tumors account for most breast cancers and develop in the inner luminal cells 
lining the mammary ducts of breast.  These tumors characteristics tend to be positive in estrogen 
(ER+) and/or progesterone (PR+) receptors, human epidermal growth factor receptor 2 
(HER2/neu-) and have a low or moderate tumor grade.  Of the four subtypes, luminal A tumors 
tend to have the best prognosis, with higher survival rates and low recurrence (Susan G. Komen 
Foundation, 2013b). 
 Luminal B tumors also develop in the inner luminal cells lining the mammary ducts of 
breast.  However, these tumors are highly positive for Ki67 and/or HER2/neu-positive.  Ki67 is a 
protein strictly associated with cell proliferation that is present during all active phases of the cell 
cycle (Scholzen, 2000).  High levels of this protein, Ki67, increases the number of cancer cells 
actively dividing, resulting in recurrence of this tumor.  The other characteristics found in 
luminal A tumors remain the same in luminal B, ER+ and/or PR+ and HER2/neu-.  Younger 
women are often diagnosed with luminal B tumors and have a poorer prognosis due to a poorer 
tumor grade, larger tumor size, positive lymph nodes and p53 gene mutations.  Although those 
diagnosed with luminal B breast cancer have a poorer prognosis, they usually have a fairly high 
survival rate (Susan G. Komen Foundation, 2013b). 
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 HER2 type tumors are named for their positive HER2/new status.  Characteristics include 
negative ER and PR, positive lymph nodes and a poor tumor grade.  Along with these factors, 
75% of HER2 tumors contain a p53 mutation and occur in about 10-15% of breast cancers.  
HER2 tumors are diagnosed in women younger than those with luminal A and B tumors.  These 
women have a fairly poor prognosis and are prone to early and frequent recurrence and 
metastases (Susan G. Komen Foundation, 2013b). 
 Basal-like tumors develop in the outer (basal) cells lining the mammary ducts of breast.  
These tumors tend to express HER1 and/or cytokeratin 5/6 proteins and most contain p53 
mutations (Susan G. Komen Foundation, 2013b).  Basal-like tumors tend to have similar 
characteristics to triple negative tumors.  However, not all triple negative tumors are basal-like 
and not all basal-like tumors are triple negative.  But whether basal-like or triple negative, 15-
20% young African American women are diagnosed with this breast cancer.  In comparison to 
the estrogen receptor-positive subtypes (luminal A and B), triple negative/basal-like tumors are 
often aggressive and have a poorer prognosis. 
2.3  Triple Negative Breast Cancer 
 Triple Negative Breast Cancer is characterized by the absence of ER, PR, and HER2 
receptors.  Anyone can develop TNBC, but research has shown that it occurs more often in 
younger, African American women, Hispanic/Latina women and women with breast cancer 
susceptibility gene 1 (BRCA1) mutations.  BRCA1 is a gene that normally functions as a tumor 
suppressor in humans by helping to ensure the stability of deoxyribonucleic acid (DNA) in a cell 
and prevent uncontrolled cell growth.  Mutations made to this gene make one more susceptible to 
the development of cancer.  TNBC is often a very aggressive tumor in comparison to other breast 
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cancer subtypes.  This cancer is often more likely to metastasize to other parts of the body 
quickly.  It also seems to recur more often than other subtypes of breast cancer. 
 Because of the lack of hormone receptors present in TNBC, treatment options are limited.  
TNBC is insensitive to most of the known effective therapies available for breast cancer 
treatment including HER2-directed therapy such as trastuzumab and endocrine therapies such as 
tamoxifen or aromatase inhibitors due to the lack of these receptors present (National Cancer 
Institute, Breast).  Like most cancers, TNBC can be successfully treated if caught early, however 
the need for other targeted therapies for this type of breast cancer is still present. 
 Creating therapeutics for TNBC will instead target the affected pathways rather than the 
non-present receptors.  Research found some of the most significant regulators of TNBC to be 
angiotensinogen (AGT), nuclear factor-kappa B (NF-κB), platelet derived growth factor receptor 
(PDGFR), and protein 53 (p53) pathways (Ossovskaya, 2011).  AGT has been reported to 
significantly increase angiogenic proteins in receptor-negative cells.  These proteins function in 
the process of angiogenesis, the formation of new blood vessels.  The relationship between AGT 
and breast cancer has not yet been previously well characterized.  However changes in NF-κB, 
PDGFR and p53 have been previously reported.  NF-κB is a transcription factor involved in 
many functions, including stress-induced, immune, and inflammatory responses, development of 
certain hemopoietic cells, keratinocytes, and lymphoid organ structures, neoplastic progression, 
tumorigenesis, and an important regulator in cell fate (Baldwin, 1996).  In cancer, NF-κB 
activation has been linked to cell proliferation, survival, invasion, and angiogenesis, resulting in 
a desirable target for therapy (Brown, 2008).  PDGFRs’ coincide with platelet derived growth 
factors (PDGF) that play an important role in development, cell proliferation, cell migration and 
angiogenesis.  PDGFs act via two receptor tyrosine kinases with common domain structures, 
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platelet derived growth factor receptor-alpha (PDGFR-α) and platelet derived growth factor 
receptor-beta (PDGFR-β), each having a distinct function in inducing several signaling pathways 
(Andrae, 2008).  While p53 is a tumor suppressor gene that has been found to be mutated in 
more than 50% of human cancers and the most mutated gene in TNBC (Azvolinsky, 2012; Bai, 
2006).  It has also proven to be a key regulator in the induction and progression of apoptosis. 
2.4  p53, a tumor supressor 
 p53 is a nuclear phosphoprotein with a molecular weight 53 kDa (kilodaltons).  The gene 
is 20 kilobases (kb) long and contains 11 exons with the first and second exons being separated 
by a 10 kb intron (Lamb, 1986).  This gene can be found on the small arm of chromosome 17, 
and contains 393 amino acids, consisting of three functional domains: the N-terminus, central 
core, and C-terminus (Bai, 2006).  The amino-terminus (N-terminus) contains an amino-terminal 
transactivation domain (residues 1-42) and a proline-rich region (residue 61-94).  The central 
core (residues 102-292) is made up of DNA-binding domain required for sequence-specific DNA 
binding.  This domain is frequently mutated in human cancer cells and tissues and highly 
conserved.  The carboxyl-terminus (C-terminus) contains the tetramerization domain (residues 
324-355), regulatory domain (residues 363-393), a nuclear localization signal sequence (NLS), 
and 3 nuclear export signal sequence (NES).  This region is thought to perform regulatory 
functions as well as posttranslational modifications to residues, such as phosphorylation and 
acetylation.  The C-terminus also functions as a negative regulator by regulating the ability of the 
core DNA binding domain to lock the DNA binding domain in a dormant conformation.  If this 
interaction is interrupted by a posttranslational modification, the DNA binding domain becomes 
active, inducing enhanced transcriptional activity (Bai, 2006). 
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 p53 is involved in multiple central cellular processes, including transcription, DNA 
repair, genomic stability, senescence, cell cycle control, and apoptosis.  As a transcription factor, 
p53 domains are responsible for recognizing and binding to specific DNA elements and 
interacting with components found in the transcriptional machinery and activation.  By binding 
to these regions, p53 can either activate some genes, or repress transcription of others 
(Chumakov, 2007).  These processes occur in response to the induction of regulatory genes that 
are activated or repressed by p53.  The activity of p53 must also be tightly regulated and 
controlled to prompt the desired results on cell growth and other processes.  Regulation of p53 is 
seen more at the protein level with stability, control of subcellular localization, posttranslational 
modifications, and conformational changes that allow activation of DNA binding (Woods, 2001). 
Many transcription factors are also responsible for regulating p53 expression such as NF-κB, 
homeobox A5 (HOXA5) and murine double minute 2 (MDM2).   
 MDM2 has been deemed the master regulator for the stability of p53.  This gene interacts 
with the N-terminal region and functions as an ubiquitin ligase for p53 (Woods, 2001).  MDM2 
is said to participate with the export of p53 from the nucleus to the cytoplasm, where degradation 
of p53 occurs.  Many tumors have shown increased expression of MDM2, thus inactivating the 
apoptotic and cell cycle arrest functions of p53, as seen with deletion and mutations of p53 
(Iwakuma, 2003).  
 With mutations seen in p53, the normal function of arresting the growth of cells that 
contain damaged DNA is compromised.  However the presence of wild-type p53 is a strong 
indicator of apoptosis.  The p53 signaling pathway remains in ‘standby’ mode under normal 
cellular conditions, only becoming activated in response to cellular stress and distinct regulatory 
kinases found upstream.  Some of these include an ataxia telangectasia mutated (ATM)/human 
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homologue of Rad53 checkpoint kinase 2(Chk2)-dependent pathway activated by DNA double-
strand breaks, p14ARF, an alternative product of the INK4 gene, activated by expression of 
oncogenes, and a third pathway whose activity is increased by cytotoxic anti-tumor agents and 
ultraviolet (UV) light, but is independent of the previous pathways mentioned (Gasco, 2002). 
 In apoptosis, p53 can initiate, if DNA damage is proved to be irreparable.  p53 affects 
both the extrinsic and intrinsic/mitochondrial pathways by either repressing or activating several 
different genes involved in the apoptosis process.  The extrinsic pathway can be regulated via 
p53 activating transcription of apoptotic protease activating factor 1 (APAF1) gene and 
increasing the sensitivity to extrinsic proapoptotic ligands by stimulating transcription of FAS 
(also known as apoptosis antigen 1 (APO1)) and KILLER (also known as death receptor 5 
(DR5)) genes (Chumakov, 2007).  While p53s role in the intrinsic pathway involves repressing 
transcription of B-cell lymphoma 2 (Bcl2), an anti-apoptotic protein, and activating transcription 
of proapoptotic proteins Bcl2-associated X protein (Bax), Noxa, p53-regulated Apoptosis-
Inducing Protein 1 (p53AIP1), and Puma (Chumakov, 2007).  Deviations of the many pathways 
that regulate p53 activity, such as the activation of oncogenes Reticular activating system (Ras) 
and Myelocytomatosis (Myc), or the loss of tumor suppressor genes retinoblastoma protein (Rb) 
and ADP Ribosylation Factors (ARF) lead to the activation of p53 and thus the elimination of 
normal cells.  
2.5  Poly (ADP-ribose) Polymerase & PARP Inhibitors 
 Poly (ADP-ribose) Polymerases (PARPs) are a family of enzymes involved in DNA 
repair via the base excision repair (BER) pathway.  In the late 1980s, PARP was isolated.  
PARPs use nicotinamide adenine dinucleotide (NAD+) as a substrate to transfer ADP-ribose onto 
glutamic acid residues of proteins (Smith, 2001).  Of this family, the most well-known and 
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studied enzyme is PARP-1.  PARP-1 plays a key role in repairing single-stranded DNA breaks 
through BER.  It is a 116 kDa protein that contains three main functional domains: a DNA-
binding domain, automodification domain (N-terminal), and catalytic domain (C-terminal) 
(Hong, 2004) (Figure 2). 
 
Figure 2. PARP-1 Structure 
 The DNA-binding domain utilizes three zinc-finger motifs that recognized single or 
double-stranded breaks in DNA (D’Amours, 1999). This domain also contains a nuclear 
localization signal (NLS).  The auto-modification domain (AMD) serves as the target of covalent 
auto-poly(ADP-ribosyl)ation.  Whereas the catalytic domain (C-terminal) catalyzes poly(ADP-
ribosyl)ation reactions using NAD+ molecules as a donor of ADP-ribose groups (Kim, 2005).  
All together these domains allow PARP-1 to interact with DNA and chromatin, poly(ADP-
ribosyl)ate a variety of nuclear target proteins and regulates nuclear functions (Kraus, PARP-1).   
PARP-1 can function in regulating gene expression, amplification, cellular differentiation, 
malignant transformation, cellular division, DNA replication, mitochondrial function, and cell 
death.  Under physiological conditions, inactive PARP-1 resides in the nucleoplasm.  Breaks in 
DNA strand trigger the synthesis of poly(ADP-ribose) at sites if breakage, and PARP-1 binds 
tightly to nicked DNA (Smith, 2001).   
 PARP inhibitors mimic the nicotinamide moiety of NAD and bind to the enzyme’s 
catalytic domain, inhibiting automodification and subsequent release of the enzyme from the 
DNA damage site (Kummar, et al., 2012).  PARP inhibitors also prevent other repair proteins 
 16 
from gaining access to sites of DNA breaks.  PARP inhibition enhances the therapeutic index of 
cytotoxic chemotherapy only if the DNA damage is significantly increased in tumor compared to 
normal tissues (Kummar, et al., 2012).  Therefore, the opportunity for PARP inhibitors to have 
the greatest killing affect and selectivity is vastly improved in tumors that already have DNA 
repair defects.  Synthetic lethality is the term describing simultaneous dysfunction of two DNA 
damage repair pathways that decreases the ability of tumor cells to withstand the DNA damage 
produced during normal cellular replication (Iglehart, 2009).   Two genes are said to be in a 
synthetic lethal relationship if a mutation in either gene alone is not lethal but mutations in both 
cause the death of the cell (Iglehart, 2009).  For tumors harboring somatic or germline defects in 
non-BER DNA damage repair pathways, synthetic lethality can be accomplished with PARP 
inhibitors simultaneously blocking BER and non-BER pathways.  The schematic seen in figure 3 
describes the mechanisms cell death from synthetic lethality in normal cells, BRCA mutated 
cells, PARP inhibited cells, and cells with both defects (Iglehart & Silver, 2009). 
 
Figure 3. Synthetic Lethality Scheme 
 As shown in cases A-C, DNA repair is achieved due to the compensation of functioning 
of repair pathways, BER and/or homologous repair (HR).  However in case D, the absence or 
BRCA along with the inhibition of PARP results in cell death due to the inability of both repair 
pathways (Figure 3). 
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 PARP inhibitors have the ability to selectivity create cell death in tumors that have 
mutations to specific genes such as, BRCA1 or BRCA2.  These patients are perfect candidates 
for treatment in being highly sensitive to this treatment through synthetic lethality resulting in 
apoptosis. 
2.6  Apoptosis 
 Apoptosis is defined as programmed cell death characterized by distinct morphological 
characteristics and energy-dependent biochemical mechanisms.  The term was first used in a 
paper written by Kerr, Wyllie, and Currie in 1972 to describe a morphologically distinct form of 
cell death (Elmore, 2007).  The normal function of apoptosis is to serve as a homeostatic 
mechanism during development and aging, and results in maintaining cell populations in tissues.  
It also serves as a defense mechanism to immune reactions or cell damage caused by disease or 
other agents.  Some stimuli and conditions that can trigger apoptosis can include irradiation, 
chemotherapeutics, and/ or hormones.  Although a variation of things can initiate apoptosis, not 
all cells will die or even be affected by the same stimulus.  
 The apoptotic mechanism has two main pathways, extrinsic and intrinsic, that are highly 
complex and sophisticated.  The extrinsic pathway is also known as the death receptor pathway 
and involves mediated interactions with transmembrane receptors.  These receptors include 
members of the tumor necrosis factor (TNF) receptor gene superfamily.  Members of this family 
share a similar cystein-rich extracellular domain and have a cytoplasmic domain of ~80 amino 
acids called the “death domain” (Ashkenazi, 1998).  This domain plays a critical role in 
transmitting the death signals from the cell surface to the intracellular signaling pathways.  The 
extrinsic pathway involves the ligands and corresponding death receptors Fas ligand (FasL)/Fas 
receptor (FasR) and Tumor necrosis factor alpha (TNF-α)/Tumor necrosis factor receptor 
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(TNFR1).  In these models, clustering of receptors and binding with the homologous trimeric 
ligand occurs.  Upon the ligand binding, cytoplasmic adapter proteins are recruited to bind with 
the receptors.  The binding of FasL to FasR results in the binding of the adapter protein Fas-
associated protein with Death Domain (FADD) and the binding of TNF ligand to TNF receptor 
results in the binding of the adapter protein Tumor necrosis factor receptor type 1-associated 
death domain (TRADD) with recruitment of FADD and Receptor-interacting Protein (RIP).  
FADD then connects with procaspase-8 via dimerization of the death effector domain.  At this 
point, a death-inducing signaling complex (DISC) is formed, resulting in the autocatalytic 
activation of procaspase-8 (Kischkel, et al., 1995).  Once caspase-8 is activated, the execution 
pathway of apoptosis is triggered. 
 The intrinsic pathway is also known as mitochondrial pathway and involves a diverse 
assortment of non-receptor mediated stimuli that produces intracellular signals that act directly 
on targets within the cell and are mitochondrial-initiated events (Elmore, 2007).  These stimuli 
produce intracellular signals that may act in either a negative or positive manner.  Negative 
signals result from the absence of certain growth factors, hormones and cytokines that lead to 
failure of suppression of death receptors and trigger apoptosis.  While stimuli that act in a 
positive manner include, but are not limited to, radiation, toxins, hypoxia, hyperthermia, viral 
infections, free radicals and DNA damage.  This pathway involves a cascade of proteins that 
induce apoptosis.  A healthy cell is characterized by mitochondria’s outer membrane containing 
Bcl-2 on its surface. The Bcl-2 protein functions in inhibiting apoptosis within a health cell.  
However in a damaged cell, the protein Bax, migrated to the surface, inhibits Bcl-2 and creates 
holes within the mitochondrial membrane causing cytochrome c to leak out.  The cytochrome c 
then binds to apoptotic protease activatin factor-1 (Apaf-1) and forms a complex known as 
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apoptosomes.  Apoptosomes in turn bind to and activate caspase-9, which functions in cleaving 
proteins.  As Caspase-9 cleaves proteins it activates other caspases in an expanding cascade that 
results in digestion, degradation, and phagocytosis of the cell.  
2.7  Styrene 
 These styrenes, also known as 3-nitro-2-styrlbenzoic, are acid derivatives that are 
precursors to indole and share the same structural motif as a well-known chemopreventive, 
resveratrol.  The structure for indole is a bicyclic aromatic with a nitrogen pyrole group (Figure 
4).   
 
Figure 4. Indole Structure 
Resveratrol (3.5.4’-trihydroxy-trans-stibene) (Figure 5) is a stilbenoid and natural polyphenol 
present in the skin of grapes and red wine (Horvath, 2004).      
 
Figure 5. Resveratrol Structure 
 Resveratrol can also be found in food products and beverages such as peanut butter, dark 
chocolate, and grape juice.  Phenols are of particular interest in the development of 
chemopreventives.  Resveratrol is an important structure to use as a building block for new 
chemopreventives due to its proven effectiveness in biological function.  Resveratrol possesses 
1 
2 
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antioxidant activity and may decrease reactive oxygen species production in blood platelets and 
oxidant-induced apoptosis (Stivala, et al., 2001).  It can also inhibit platelet aggregation induced 
by thrombin, collagen, and adenosine diphosphate and reduce inflammation by inhibiting 
prostaglandin production, cyclooxygenase-2 activity and nuclear factor-B activity (King-
Bioactivity).  In addition to antioxidant and anti-inflammatory properties, resveratrol can inhibit 
D-type cyclins and cyclin-dependent kinase (Cdk) 4 expression (Lee, 2008; Liang, 2007). This 
can also lead to inducing tumor suppressors, p53, and Cdk inhibitor, protein 21 (p21).  
These stilbene-based molecules are widely found in nature and have a versatile function in many 
biological activities.  The styrene derivatives used, have a trans-stilbene structure with 
biologically active amide and nitro groups in addition to electron withdrawing or donating 
substituents on the second ring.  The substituents on ring 2 are biologically active and naturally 
occurring in the body.  A push-pull mechanism will result from placement of these groups to 
stabilize the styrene structure.  Due to the structural similarities, with substituents at the ortho-, 
meta- and para- positions (as seen in Figure 6), it is likely; the 3-nitro-2-stryrlbenzoic acid 
derivatives will be effective chemopreventives. 
   
Figure 6. Relative Positions on Benzene Ring 
Theses derivatives will maximize the biological activity without increasing cytotoxicity in the 
body. 
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CHAPTER 3 
Material & Methods 
3.1  Cell Lines 
  Human breast cancer cell lines HCC1806 and HCC70 were used throughout this project 
and purchased from the American Type Culture Collections (Manassas, VA).   Both cell lines are 
classified as triple negative breast cancer.  HCC1806 was derived from a 60-year-old African 
American female suffering from primary squamous cell carcinoma.  HCC1806 lacks the 
expression of ER, PR, and HER2 receptors. HCC70 is basal A subtype breast cancer cell line 
derived from the mammary gland of a 49-year-old African American female suffering from 
primary ductal carcinoma.  This cell line lacks the expression of ER, PR, and HER2 as well.  
Both cell lines were grown in Roswell Park Memorial Institute (RPMI)-1640 (Thermo Scientific; 
Rockford, IL) that contains 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin 
(P/S) (Bio Express: Kaysville, UT). 
3.2  Styrene Compounds 
 Styrene compounds used as treatments were chemically synthesized.  Each compound 
consisted of the common Methyl-2-methyl-3 nitrobenzoate reactant plus an additional type of 
benzaldehyde reactant to produce a (E)-3-nitro-2-styrylbenzoic acid product (labeled JKS 1.001, 
-1.006, -1.007, -1.009) as seen in the general reaction (Figure 7). 
 
Figure 7. Styrene General Reaction 
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 Compound JKS 1.001 was synthesized by reacting methyl-2-methy-3-nitobenzoate and 
2,3-demethoxybenaldehyde in the presence of base to yield 2-[trans-2-(2,3-dimethylphenyl)-
vinyl]-3-nitrobenzoic after sufficient workup. Compound JKS 1.006 was synthesized by reacting 
methyl-2-methy-3-nitobenzoate and 4-chlorobenzaldehyde in the presence of base to yield 2-
[trans-2-(4-chlorophenly)-vinyl]-3-nitrobenzoic after sufficient workup.  Compound JKS 1.007 
was synthesized by reacting Methyl-2-methy-3-nitobenzoate and 2-methoxybenzaldehyde in the 
presence of base to yield 2-[trans-2-(methoxyphenyl)-vinyl]-3-nitrobenzoic after sufficient 
workup.  Compound JKS 1.009 was synthesized by reacting methyl-2-methy-3-nitobenzoate and 
2-(Trifluoromethyl) benzaldehyde in the presence of base to yield 2-[trans-2-(2-
9trifluormethylphenyl)-vinyl]-3-nitrobenzoic after sufficient workup (Figure 8).   
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Styrene Compounds  
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3.3  Chemotherapeutic Drug Treatments 
 Each compound was diluted in dimethyl sulfoxide (DMSO) to attain a stock 
concentration of 1000 µM.  The following amount of grams was dissolved in 2 ml of DMSO to 
bring the molarity to approximately 1000 µM (Table 1). 
Table 1  
Styrene Preparations 
Treatment/Chemical Molecular Weight (g/mol) Amount Used (g) 
JKS 1.001 329.19 0.0006 
JKS 1.006 303.70 0.0006 
JKS 1.007 299.28 0.0007 
JKS 1.009 337.25 0.0008 
  
  The working concentration was further diluted into a 100 and 10 µM for further titration 
treatments.  Adherent cells were exposed to chemical treatments.  Following exposure, cells were 
photographed using at Phase-Contrast Microscope at 10x and 20x magnification to assess 
physical apoptosis.  Treatments were pipetted on 10 cm plates for each cell line and incubated up 
to 24 h at 37 (°C) and 4% carbon dioxide (CO2).  Floating or dead cells were collected and 
adherent cells were washed with 3 ml of 1X Phosphate Buffer Saline (PBS).  All washes were 
collected and held for further analysis.  Approximately 2 ml of trypsin (Hyclone Laboratory; 
Logan, UT) was added to the plates and incubated until cells detached from plate.  To stop 
trypsin action, 2 ml of media was added to each plate.  The chemically treated media, 1X PBS, 
trypsin, and fresh media were all collected in a designated 15 ml conical per treatment and mixed 
via pipette.   
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3.4  Cell Viability 
 Following treatment, cells were analyzed using the VI-Cell XR Viability Analyzer to 
quantify apoptotic cells.   500 µl of each treatment was placed into labeled sample cups, in 
triplicates (total of 15 sample cups).  Nine sample cups were placed in the VI-Cell XR Cell 
Viability Analyzer at a time and analyzed following the user’s manual protocol. (CMCresson, 
User Instructions)  The remaining solution within each conical were aliquot out amongst 6 
eppendorf tubes per treatment (totaling 36 tubes including both untreated control and vehicle 
control per concentration).  Eppendorf tubes were centrifuges at 5,000 rpms for 5 minutes to 
produce pellets.  Supernatant was removed from each eppendorf again with the aspirator 
vacuum. Eppendorfs were stored at -80ºC. 
3.5  MTT Assay 
 Cells were grown on a 96-well plate for 24 hours.  MTT solution was added to each well 
and incubated at 37ºC in 4% CO2 for approximately 4 hours.  Solution C was then added to each 
well and incubated for up to an hour.  Absorbance was measured at wavelengths of 570 and 630 
nm with an enzyme-linked immunosorbent assay (ELISA) plate reader.  
3.6  HT Fluorescent PARP Inhibition Assay (HFHPIA) 
 Styrene compounds were analyzed with Trevigen’s HT F Homogeneous PARP Inhibition 
assay kit to determine the PARP inhibition potential.  The Trevigen protocol was followed with 
some changes to accommodate using DMSO as a solvent for the styrene compounds.  A black 
96-well microplate along with all reagents was provided. The protocol was followed except a 
change in concentration levels due to the lack of availability of the styrene compounds.  
Concentrations were reduced to 5, 15 and 25x.   
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CHAPTER 4  
Results 
4.1  To identify the apoptotic effect of these styrene compounds and the most effective 
working concentration. 
 Following 24 hours, both cell lines (HCC1806 and HCC70) treated at various 
concentrations (10, 100, and 1000 µM) were visualized at 20x magnification under a Phase-
Contrast Microscope (Figures 9-14).  Exposure of breast cancer cell lines to styrene compounds 
demonstrates apoptosis within a 24 hour time period.  Qualitative analysis determined an 
approximation of the amount of apoptosis produced by each styrene compound based upon 
apoptotic characteristics seen in the images such as undefined shape and clustering of the cells.   
 At a concentration of 10 µM, cell line HCC70 qualitative analysis exhibited compound 
1.006 yielding the greatest amount of apoptosis due to morphological integrity of the cells within 
a 24 hour time period (Figure 9).  Cell line HCC1806 exhibited compound 1.007 yielding the 
greatest amount of apoptosis within 24 hours (Figure 10). 
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Figure 9. Qualitative Analysis of HCC70 at 10 µM.  
 
Figure 10. Qualitative Analysis of HCC1806 at 10 µM.   
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 At a concentration of 100 µM, cell line HCC70, qualitative analysis exhibited compound 
1.009 yielding the greatest amount of apoptosis.  In cell line, HCC1806, 1.007 yielded the 
greatest amount of apoptosis  (Figures 11 & 12). 
 
Figure 11. Qualitative Analysis of HCC70 at 100 µM 
 
Figure 12. Qualitative Analysis of HCC1806 at 100 µM  
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At a concentration of 1000 µM, cell line, HCC70, exhibited compound 1.009 yielding the 
greatest amount of apoptosis. While cell line HCC1806, exhibited compound 1.007 yielding the 
greatest amount (Figures 13 & 14). 
 
Figure 13. Qualitative Analysis of HCC70 at 1000 µM 
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Figure 14. Qualitative Analysis of HCC1806 at 1000 µM  
 Following qualitative analysis, quantitative analysis was performed and analyzed with the 
VI-Cell XR Viability Analyzer (Figures 15-20).  Quantitative analysis confirmed cell viability of 
each cell line following 24-hour exposure to each styrene at various concentrations.  Viability 
percent describes the amount of cells living, calculated as the percent viability value subtracted 
from 100 resulting in the Apoptosis Percentage (%).    
 Quantitative analysis at 10 µM confirms compound 1.006 to exhibited the greatest 
amount of apoptosis in HCC70 cell line.  However, in the HCC1806 cell line, compound 1.001 
exhibited the greatest amount of death (Figures 15 &16). 
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Figure 15. Quantitative Analysis of HCC70 at 10 µM 
 
Figure 16. Quantitative Analysis of HCC1806 at 10 µM 
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 Quantitative analysis show in both cell lines that compound 1.009 yielded the maximum 
apoptotic effect at 100 µM Figures 17 & 18. 
 
Figure 17. Quantitative Analysis o HCC70 at 100 µM 
 
Figure 18. Quantitative Analysis of HCC1806 at 100 µM 
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 Quantitative analysis shows that both compounds yielded maximum apoptotic effect at 
1000 µM in Figures 19 & 20.  The 70-cell line had a significant amount of apoptosis in 
compound 1.009 and the 1806-cell line in compound 1.007.  
 
Figure 19. Quantitative Analysis of HCC70 at 1000 µM 
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Figure 20. Quantitative Analysis of HCC1806 at 1000 µM 
 From here, we were able to identify the working concentration in both triple negative cell 
lines.  For 70, the working concentration was 100 µM and for 1806, 10 µM.   
 An MTT assay was then performed with both cell lines at 100 µM.  Results indicate that 
compounds 1.007 (HCC70) and 1.009 (HCC1806) yield the greatest amount of apoptosis at the 
100 µM concentration (as seen in Figures 21 & 22). 
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Figure 21. HCC70 MTT Assay at 100 µM 
 
Figure 22. HCC1806 MTT Assay at 100 µM  
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4.2  To identify PARP Inhibition potential of each styrene compound. 
  HFHPIA was used to determine whether these compounds were PARP inhibitors.  
Results determine all compounds at various concentrations (5, 15 & 25x) are PARP inhibitors 
(Figure 23). 
 
Figure 23. HT Fluorescent Homogeneous PARP Inhibition Assay  
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CHAPTER 5 
Discussion 
 Experimental data have shown these styrene compounds to have an apoptotic effect on 
triple negative breast cancer cell lines, HCC1806 and HCC70.  Although the results vary per 
compound and concentration, there is a significance seen in the cell death versus viable cells 
(Table 2).  
Table 2 
Summary of Styrene Compounds that produces the greatest amount of apoptosis 
 
 Although we do not see one common styrenyl compound yielding a great amount of 
apoptosis in both cell lines throughout this study, we see that each compound induces apoptosis 
within these TNBC cell lines.  We can also determine at which concentration we produce the 
best results within a 24-hour period (Table 3). 
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Table 3  
Summary of the best working concentration for cell lines HCC70 & HCC1806 
(Numbers indicate Average Percent Viability) 
 
 5.1  Styrene compounds produce apoptosis in both HCC1806 and 70 cell lines.  
 Compounds 1.007 and 1.009 resulted in the greatest amount of apoptosis at a molar 
concentration of 100 µM in HCC70 and 1806, respectively.  We verify this with a Cell Viability 
and MTT assay.  The cell viability quantified the amount of apoptosis seen within each cell line 
and at various concentrations.  It was expected that the styrene compounds would cause death in 
these cells within a given time.  When identifying the working concentration the results we 
expected were not potrayed.   In many drug development studies, the lower concentration is used 
most often because lower treatments are often used in in-vitro studies to caution the effect of the 
drug on normal healthy cells.  We saw this in the HCC1806 cell line, where the most apoptosis 
was seen with each styrene compound at 10 µM.  HCC1806 is a well-known TNBC cell line, 
with a different p53 status than HCC70.  The p53 protein in HCC1806 contains a frame-shift 
mutation, where an insertion of 2 base pairs occurs at exon 7 codon 256.  A difference is seen in 
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the p53 status of HCC70, where there is a missense (or point) mutation, where one single 
nucleotide is changed, at exon 7 codon 248 from GAC→CAC (Lacroix, 2006).  The difference 
in p53 status could have an effect on the apoptotic effect of these compounds on these TNBC 
cell lines, since we know p53 play a major role as a regulator in the intrinsic apoptotic pathway.  
After a certain amount of time all cells will go into apoptosis due to other stress factors.  This can 
be further analyzed by treating tells at different time points (ex. 8, 12, or 48 hours) other than the 
24 hours period used here. 
 The focus then turned to the 100 µM concentration for further testing on apoptosis with 
these compounds.  This concentration was chosen for further testing because it played the 
median between the other two concentrations initially used.  Through observation we were able 
to direct the attention to certain styrene compounds that can be used in further testing.  At 100 
µM, compounds 1.007 and 1.009 exhibit the greatest amount of apoptosis after performing a 
MTT Assay (Figures 21 & 22).  Both styrene compounds, 1.007 and 1.009, are the most 
mentioned in Table 2 with both cell lines at the higher concentrations.  
 
 
 
 
 
 
 
 
 
 Figure 24. Styrene Compounds 1.007 & 1.009 
 Both of these compounds differ from the other 2 compounds by the ortho positioning of 
the substituents on the second benzene ring.  However, each (1.007 and 1.009) has a different 
substituent at this position, methoxy and trifluoromethyl.  (as seen in Figure 26)  Each of these 
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functional groups could also play a role in its effect on these TNBC cell lines.  Although each of 
these theories has not been analyzed in this study, what we do know is that each of these 
compounds, along with the other two, has an apoptotic effect on HCC70 and 1806.  
5.2  Styrene compounds are identified as PARP inhibitors based upon the HT Fluorescent 
Homogenous PARP Inhibition Assay. 
 In this assay, inhibitors are identified by an increase in fluorescent signal when PARP 
mediated NAD+ depletion is inhibited.  The level of NAD+ is coupled to a cycling assay 
involving alcohol dehydrogenase and diaphorase.  Each time NAD+ cycles through these coupled 
reactions, a molecule of highly fluorescent resorufin is generated (from the non-fluorescent 
substrate, resazurin).  In the presence of the PARP enzyme (plus PARP) the NAD+ fluorescent 
signal vastly decreases, in comparison to the inhibitor control where the signal increases. The 
known inhibitor used is able to block the impact of PARP.  The assay interprets the data 
collected from the fluorescence plate reader (at 590 nm) as a median between the plus PARP and 
inhibitor control.  Therefore results from this assay show each styrene compound at various 
concentrations (5, 15 and 25x) are PARP inhibitors.  It is also shown with this assay that the 
lower concentrations of these compounds have a greater PARP inhibitor potential than the higher 
concentrations.  This is the same trend that was seen with the apoptotic effect of these styrene 
compounds at the various molar concentrations previously.  However this assay was not affected 
by the difference in cell lines.  HFHPIA is solely based on the styrene compounds composition, 
structure, and concentrations. 
 This study successfully identified the apoptotic effect and the PARP inhibitor potential of 
these styrene compounds.  Future directions would include 1) setting time points 2) performing 
titrations at lower concentrations 3) comparing compounds to known PARP inhibitors 4) analyze 
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the effect on these compounds in different breast cancer cell lines as well as healthy cell lines.  
Analyzing these cells at different time points will acquire the point at which the cells first begin 
to degrade and progress into cell death.  We can also examine the effect these compounds will 
have in treating cells for an extended amount of time (i.e. 48 hours).  Since most drug 
development uses the lowest concentration in clinical settings, titration of these drugs to lower 
concentrations to see if they still have an apoptotic effect is the next step in developing a novel 
chemotherapeutic.  We can then test these compounds next to known PARP inhibitors to 
compare and contrast the effects with more knowledgeable drugs.  The effect these compounds 
have on different breast cancer cell lines as well as normal healthy cells is important in 
understanding the cytotoxity to normal cells and the potential therapies used in other cancers.   
 In summary, this study was preliminary work for the treatment of TNBC with these 
styrene compounds.  Results revealed these compounds as a possible novel chemotherapeutic in 
TNBC.  Identifying a novel target therapy for TNBC will initiate clinical studies and create a 
significant impact in the African-American and breast cancer research community. 
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